Study on the Response to Tetanus Vaccination of People Living With HIV

The response to primary tetanus immunization of HIV-infected children is lower than that of uninfected children.

Response to tetanus toxoid (TT) booster doses in adults living with HIV who have received primary vaccination prior to infection is not known.

Currently, it is recommended to have a TT booster for people living with HIV (PLHIV) every 10 years. In general population, this recall is made only at 25, 45 and 65 years, then every 10 years.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier de Niort

Niort, 79000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Person aged ≥ 18 years
Person infected with HIV followed in the infectious diseases department of CH Niort
Born in France
Affiliate or beneficiary of a social security scheme
Being able to give free and informed consent to participation in research

Exclusion criteria

Persons with a contraindication to tetanus vaccination
Persons under guardianship or curatorship or without civil law

Treatment and study plan

additional blood sampling

Diagnostic Test

additional blood sampling

Primary outcomes

the vaccine response to tetanus vaccination

Time frame: Month 6

An anti-tetanus IgG level> 0.1 is considered long-term protective. An anti-tetanus IgG level between 0.01 and 0.1 is considered protective in the short term.

The measurement of the vaccine response will be correlated with the age of the last VAT recall (<10 years, between 10 and 20 years,> 20 years and unknown)

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Niort

Other

Registry information

Acronym: VACTEVIH

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2020
First posted: Feb 26, 2019
Registry last updated: Oct 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed